SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Freenome, the privately held biotechnology company that has pioneered a comprehensive multiomics platform for early cancer detection using a routine blood draw, today announced results from two different studies using “CRC - Microsimulation of Adenoma Progression and Screening”, or CRC-MAPS™, a novel semi-Markov microsimulation model of the adenoma-carcinoma pathway.
The first study revealed that changes in adenoma sensitivity have a greater impact on CRC incidence and mortality reduction than changes in either CRC sensitivity or specificity. This study suggests that earlier detection of colorectal neoplasia improves clinical outcomes and highlights the benefits of preventing CRC through adenoma detection and subsequent lifelong colonoscopy surveillance.
The second study emphasized the importance of screening test adherence and the time that elapses between screening tests (test interval) on clinical outcomes. This study indicated that imperfect adherence mimics delays in screening, with both resulting in worse outcomes. These results reinforce the critical role of adherence in reducing CRC incidence and mortality, and suggest that the availability of a blood test with improved patient adherence may significantly improve clinical outcomes.
“These studies demonstrate that two features of a blood-based CRC screening test like Freenome’s—detection of advanced adenomas and greater patient adherence—can meaningfully improve the clinical benefits of CRC screening,” said Girish Putcha, M.D., Ph.D., co-author of the studies and Freenome’s Chief Medical Officer.
“This data reinforces the need for a routine, blood-based CRC test that can detect cancer early and help get more people screened,” added Mike Nolan, Freenome’s CEO. “We continue to make strong progress on PREEMPT CRC, our registrational clinical trial that aims to validate this kind of blood test to meet patient needs and improve clinical outcomes.”
Data will be presented in two posters during the 2021 Digestive Disease Week (DDW) Annual Meeting.
About the Posters
Posters about the studies will be available at https://www.freenome.com/science at the time of their presentations.
Friday May 21, 2021, 9:15am PT:
Poster #Fr450: Adenoma Sensitivity has a Greater Impact on Colorectal Cancer (CRC) Incidence and Mortality Reduction than CRC Sensitivity or Specificity: Results from a Novel Microsimulation Model
Sunday May 23, 2021, 9:15am PT:
Poster #Su061: Test Interval and Patient Participation have Comparable Impacts on Colorectal Cancer (CRC) Incidence and Mortality Reduction: Results from a Novel Microsimulation Model
About the PREEMPT CRC™ study
The PREEMPT CRC study is Freenome’s prospective clinical trial that is enrolling 25,000 average-risk individuals. The trial aims to validate a blood test that can provide an accurate, convenient, and patient-friendly option to those undergoing screening for CRC, and to support its submission for approval by the U.S. Food and Drug Administration.
Freenome is a biotechnology company that has pioneered the most comprehensive multiomics platform for early cancer detection using a routine blood draw, beginning with a colorectal cancer screening test. The company combines its deep expertise in molecular biology with advanced computational biology and machine learning techniques to detect disease-associated patterns among billions of circulating cell-free biomarkers. Freenome is also building a machine learning feedback loop with healthcare providers to leverage real-world data and improve patient care through early detection. Freenome is headquartered in South San Francisco, California.